645 related articles for article (PubMed ID: 33512650)
21. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
[TBL] [Abstract][Full Text] [Related]
22. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
Shakya A; Chikhale RV; Bhat HR; Alasmary FA; Almutairi TM; Ghosh SK; Alhajri HM; Alissa SA; Nagar S; Islam MA
Mol Divers; 2022 Feb; 26(1):265-278. PubMed ID: 33786727
[TBL] [Abstract][Full Text] [Related]
24. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
[TBL] [Abstract][Full Text] [Related]
26. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
27. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
[TBL] [Abstract][Full Text] [Related]
28. Highlights in TMPRSS2 inhibition mechanism with guanidine derivatives approved drugs for COVID-19 treatment.
Tachoua W; Kabrine M; Mushtaq M; Selmi A; Ul-Haq Z
J Biomol Struct Dyn; 2023; 41(22):12908-12922. PubMed ID: 36709428
[TBL] [Abstract][Full Text] [Related]
29. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
30. In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.
Wang S; Fang X; Wang Y
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807455
[TBL] [Abstract][Full Text] [Related]
31. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.
Huggins DJ
J Mol Graph Model; 2020 Nov; 100():107710. PubMed ID: 32829149
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Kaliamurthi S; Selvaraj G; Selvaraj C; Singh SK; Wei DQ; Peslherbe GH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209188
[TBL] [Abstract][Full Text] [Related]
33. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2 Activates Hemagglutinin-Esterase Glycoprotein of Influenza C Virus.
Sato K; Hayashi H; Shimotai Y; Yamaya M; Hongo S; Kawakami K; Matsuzaki Y; Nishimura H
J Virol; 2021 Oct; 95(21):e0129621. PubMed ID: 34406864
[TBL] [Abstract][Full Text] [Related]
35. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
Zhao H; To KKW; Lam H; Zhou X; Chan JF; Peng Z; Lee ACY; Cai J; Chan WM; Ip JD; Chan CC; Yeung ML; Zhang AJ; Chu AWH; Jiang S; Yuen KY
Nat Commun; 2021 Mar; 12(1):1517. PubMed ID: 33750821
[TBL] [Abstract][Full Text] [Related]
36. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
37. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
Choi Y; Shin B; Kang K; Park S; Beck BR
Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
[TBL] [Abstract][Full Text] [Related]
38. A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
Kondo A; Fujimoto KJ; Yanai T
Phys Chem Chem Phys; 2023 Aug; 25(30):20597-20605. PubMed ID: 37477571
[TBL] [Abstract][Full Text] [Related]
39. Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19.
Vuai SAH; Ogedjo MM; Isaac O; Sahini MG; Swai HS; Shadrack DM
J Biomol Struct Dyn; 2022; 40(24):13925-13935. PubMed ID: 34751094
[TBL] [Abstract][Full Text] [Related]
40. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M
PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]